| Ytd | -25.08% | |
| 1y | -70.85% |
| Open | 0.53 | Prev Close | 0.55 | Low | 0.53 | High | 0.55 | Mkt Cap | 119.60M |
| Vol | 3.71M | Avg Vol | 2.26M | EPS | -0.52 | P/E | N/A | Forward P/E | -1.28 |
| Beta | 2.87 | Short Ratio | 2.31 | Inst. Own | 73.76% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 0.68 | 200-d Avg | 0.74 | 1yr Est | 18.50 |
TNYA News
RMAT Designation Supported by Positive Interim Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-40
Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.20) per share which missed the an
Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to d
All Evaluable Patients Achieved Improvements in Multiple Hallmarks of MYBPC3-Associated HCMBenefits
Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to di
Tenaya reported early RIDGE-1 data showing reduced arrhythmias and favorable safety for TN-401 in PK
Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.09) per share which missed the an
Readout to Include One-Year Cohort 1 Results and Early Cohort 2 Data; Webcast Conference Call Planne
Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.12) per share which beat the anal
Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to d
Tenaya Therapeutics stock jumps after announcing a research collaboration with Alnylam worth up to $
Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to di
Aims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 with Longer-Term Follow-
Heart disease-focused Tenaya Therapeutics falls on high volume after pricing a $60 million offering
HC Wainwright & Co. analyst Joseph Pantginis maintains Tenaya Therapeutics (NASDAQ:TNYA) with
Chardan Capital analyst Geulah Livshits maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy an
Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to di
TN-401 was Well Tolerated at 3E13 vg/kg dose Robust Transduction and Demonstrated Increases in PKP2
Chardan Capital analyst Geulah Livshits maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy an
Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.12) per share which beat the anal
MyPEAK-1 Data Presented During Late-Breaking Session at AHA Scientific Sessions 2025 with Simultaneo
The U.S. Food and Drug Administration ("FDA") has placed a clinical hold on MyPEAKTM-1,Tenay
Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to di
Several biotech stocks are showing renewed strength over the past week, with their Momentum scores s
HC Wainwright & Co. analyst Joseph Pantginis reiterates Tenaya Therapeutics (NASDAQ:TNYA) wit
Largest Noninterventional Natural History Study of People Under 18 with MYBPC3-associated HCM with M
HC Wainwright & Co. analyst Joseph Pantginis reiterates Tenaya Therapeutics (NASDAQ:TNYA) wit
Chardan Capital analyst Geulah Livshits maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy an
Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.14) per share which beat the anal
Enrollment in Both Dose Cohorts of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Hypertrophi
Chardan Capital analyst Geulah Livshits maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy an
Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.24) per share which missed the an
HC Wainwright & Co. analyst Joseph Pantginis reiterates Tenaya Therapeutics (NASDAQ:TNYA) wit
HC Wainwright & Co. analyst Joseph Pantginis reiterates Tenaya Therapeutics (NASDAQ:TNYA) wit
TN-201 Has Been Well Tolerated at 3E13 vg/kg DoseNew Biopsy Data Reaffirm Robust Transduction and RN
Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to di
Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to di
Canaccord Genuity analyst Whitney Ijem maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and
Morgan Stanley analyst Matthew Harrison maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Overwe
Chardan Capital analyst Geulah Livshits maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy an
HC Wainwright & Co. analyst Joseph Pantginis maintains Tenaya Therapeutics (NASDAQ:TNYA) with
Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.28) per share which beat the anal
U.S. stock futures declined on Tuesday following the worst trading day of 2025 on Monday. Futures fe